

Pablo Ryan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4412755/publications.pdf>

Version: 2024-02-01

107
papers

3,493
citations

201385

27
h-index

161609

54
g-index

114
all docs

114
docs citations

114
times ranked

5725
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trend of hospitalized acute and recurrent hepatitis C in Spain. <i>Annals of Medicine</i> , 2024, 51, 68-68.	1.5	0
2	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	7
3	HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112405.	2.5	3
4	Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. <i>Liver International</i> , 2022, 42, 309-319.	1.9	7
5	Impact of early interferon- β treatment on the prognosis of patients with COVID-19 in the first wave: A post hoc analysis from a multicenter cohort. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112572.	2.5	8
6	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. <i>New England Journal of Medicine</i> , 2022, 386, 305-315.	13.9	813
7	Real-world evidence of sofosbuvir/velpatasvir as an effective and simple hepatitis C virus treatment and elimination tool in homeless populations. <i>Future Virology</i> , 2022, 17, 77-86.	0.9	2
8	Plasma miRNA profile at COVID-19 onset predicts severity status and mortality. <i>Emerging Microbes and Infections</i> , 2022, 11, 676-688.	3.0	44
9	Serological biomarkers of COVID-19 severity at hospital admission are not related to long-term post-COVID pain symptoms in hospitalized COVID-19 survivors. <i>Pain</i> , 2022, 163, 2112-2117.	2.0	10
10	A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
11	Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021. <i>Journal of Infection</i> , 2022, , .	1.7	0
12	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
13	Dynamics of HIV Reservoir and HIV-1 Viral Splicing in HCV-Exposed Individuals after Elimination with DAAs or Spontaneous Clearance. <i>Journal of Clinical Medicine</i> , 2022, 11, 3579.	1.0	2
14	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1451-1458.e4.	2.4	12
15	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). <i>Clinical Microbiology and Infection</i> , 2021, 27, 244-252.	2.8	95
16	Acute kidney injury in 3182 patients admitted with COVID-19: a single-center, retrospective, case-control study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1557-1569.	1.4	18
17	Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1046-1050.	1.3	2
18	Comparison of real-time and droplet digital PCR to detect and quantify SARS-CoV-2 RNA in plasma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13501.	1.7	20

#	ARTICLE	IF	CITATIONS
19	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. <i>Thorax</i> , 2021, 76, 920-929.	2.7	60
20	The Challenging Road to Hepatitis C Virus Eradication. <i>Journal of Clinical Medicine</i> , 2021, 10, 611.	1.0	5
21	Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1886-1892.	1.3	1
22	Systemic thrombosis in a large cohort of COVID-19 patients despite thromboprophylaxis: A retrospective study. <i>Thrombosis Research</i> , 2021, 199, 132-142.	0.8	29
23	Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. <i>Journal of Clinical Immunology</i> , 2021, 41, 914-922.	2.0	100
24	Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab251.	0.4	0
25	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 783-792.	4.6	62
26	HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study. <i>International Journal of Drug Policy</i> , 2021, 92, 103134.	1.6	11
27	HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study. <i>Infectious Diseases of Poverty</i> , 2021, 10, 111.	1.5	1
28	Hepatocellular carcinoma risk in hepatitis C stage 3 fibrosis after sustained virological response with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2885-2891.	1.9	9
29	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. <i>International Journal of Drug Policy</i> , 2021, 96, 103424.	1.6	10
30	Age-Adjusted Endothelial Activation and Stress Index for Coronavirus Disease 2019 at Admission Is a Reliable Predictor for 28-Day Mortality in Hospitalized Patients With Coronavirus Disease 2019. <i>Frontiers in Medicine</i> , 2021, 8, 736028.	1.2	4
31	Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	0.6	1
32	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021, 25, 331.	2.5	23
33	Are Reduced Levels of Coagulation Proteins Upon Admission Linked to COVID-19 Severity and Mortality?. <i>Frontiers in Medicine</i> , 2021, 8, 718053.	1.2	7
34	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. <i>Biochemical Pharmacology</i> , 2021, 192, 114666.	2.0	8
35	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021, 236, 147-159.	2.2	91
36	Different HCV Exposure Drives Specific miRNA Profile in PBMCs of HIV Patients. <i>Biomedicines</i> , 2021, 9, 1627.	1.4	2

#	ARTICLE	IF	CITATIONS
37	LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2021, 8, S806-S807.	0.4	6
38	The PANDEMYC Score. An Easily Applicable and Interpretable Model for Predicting Mortality Associated With COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3066.	1.0	31
39	Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2091.	1.0	3
40	Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study. <i>BMJ Open</i> , 2020, 10, e042398.	0.8	51
41	Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1525-1536.	2.8	249
42	COVID-19 in patients with hematological malignancies: A retrospective case series. <i>International Journal of Laboratory Hematology</i> , 2020, 42, e256-e259.	0.7	19
43	HCV screening and linkage to care of homeless people in a major European city. Data from a mobile screening unit (MSU). <i>Journal of Hepatology</i> , 2020, 73, S820.	1.8	1
44	Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness. <i>Journal of Hepatology</i> , 2020, 73, S350-S351.	1.8	1
45	Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000-2015): A Nationwide Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1607.	1.0	2
46	Epidemiological trend of hepatitis C-related liver events in Spain (2000-2015): A nationwide population-based study. <i>European Journal of Internal Medicine</i> , 2020, 75, 84-92.	1.0	7
47	Health care issues affecting transgender people living with HIV: an opportunity for improvement. <i>International Journal of STD and AIDS</i> , 2020, 31, 859-865.	0.5	0
48	Gender-based vulnerability in women who inject drugs in a harm reduction setting. <i>PLoS ONE</i> , 2020, 15, e0230886.	1.1	20
49	Clinical performance of Determine HBsAg 2 rapid test for Hepatitis B detection. <i>Journal of Medical Virology</i> , 2020, 92, 3403-3411.	2.5	14
50	Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa482.	0.4	2
51	Mephedrone and chemsex: when it stops being a party and becomes a fatal problem. <i>International Journal of STD and AIDS</i> , 2019, 30, 1028-1030.	0.5	16
52	National Temporal Trend Analysis of Infective Endocarditis among Patients Infected with HIV in Spain (1997-2014): A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1167.	1.0	4
53	High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. <i>International Journal of Drug Policy</i> , 2019, 72, 181-188.	1.6	29
54	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. <i>Transplant Infectious Disease</i> , 2019, 21, e13195.	0.7	14

#	ARTICLE	IF	CITATIONS
55	THU-384-Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection. Journal of Hepatology, 2019, 70, e323-e324.	1.8	0
56	SAT-229-Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals. Journal of Hepatology, 2019, 70, e731.	1.8	3
57	Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316). Journal of Antimicrobial Chemotherapy, 2019, 74, 3044-3048.	1.3	2
58	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Na ⁺ -ve Noncirrhotic Patients With HCV Genotype 1. Open Forum Infectious Diseases, 2019, 6, ofz214.	0.4	4
59	Evaluation of the diagnostic accuracy of laboratory-based screening for hepatitis C in dried blood spot samples: A systematic review and meta-analysis. Scientific Reports, 2019, 9, 7316.	1.6	35
60	HCV-coinfection is related to an increased HIV-1 reservoir size in cART-treated HIV patients: a cross-sectional study. Scientific Reports, 2019, 9, 5606.	1.6	22
61	Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIDA 9416 Study. PLoS ONE, 2019, 14, e0220272.	1.1	31
62	Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfecting individuals. Aids, 2019, 33, 685-689.	1.0	40
63	Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 423-426.	1.3	0
64	Geriatric-HIV Medicine: the geriatrician's role. European Geriatric Medicine, 2019, 10, 259-265.	1.2	12
65	Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals. Journal of Viral Hepatitis, 2018, 25, 818-824.	1.0	10
66	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. Journal of Viral Hepatitis, 2018, 25, 699-706.	1.0	15
67	All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfecting subjects in real-world practice: Madrid coinfection registry findings. Hepatology, 2018, 68, 32-47.	3.6	64
68	Evaluation of dried blood spot samples for screening of hepatitis C and human immunodeficiency virus in a real-world setting. Scientific Reports, 2018, 8, 1858.	1.6	34
69	High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit. Aids, 2018, 32, 1157-1163.	1.0	3
70	Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study. AIDS Patient Care and STDs, 2018, 32, 112-118.	1.1	84
71	Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997-2013): A nationwide population-based study in Spain. European Journal of Internal Medicine, 2018, 48, 69-74.	1.0	3
72	Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study. Scientific Reports, 2018, 8, 12137.	1.6	4

#	ARTICLE	IF	CITATIONS
73	Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder. <i>Hepatic Medicine: Evidence and Research</i> , 2018, Volume 11, 1-11.	0.9	8
74	HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. <i>PLoS ONE</i> , 2018, 13, e0204795.	1.1	10
75	The IL7RA rs6897932 polymorphism is associated with progression of liver fibrosis in patients with chronic hepatitis C: Repeated measurements design. <i>PLoS ONE</i> , 2018, 13, e0197115.	1.1	10
76	Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. <i>PLoS ONE</i> , 2018, 13, e0198768.	1.1	3
77	Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. <i>Clinical Microbiology and Infection</i> , 2017, 23, 672.e1-672.e11.	2.8	25
78	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 853-861.	1.3	4
79	Epidemiology and prognosis of candidaemia in elderly patients. <i>Mycoses</i> , 2017, 60, 808-817.	1.8	20
80	Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. <i>Clinical Microbiology and Infection</i> , 2017, 23, 49.e1-49.e8.	2.8	41
81	Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. <i>Clinical Infectious Diseases</i> , 2017, 65, 2112-2118.	2.9	88
82	CXCL9 polymorphisms are associated with liver fibrosis in patients with chronic hepatitis C: a cross-sectional study. <i>Clinical and Translational Medicine</i> , 2017, 6, 26.	1.7	13
83	Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx164.	0.4	1
84	Liver stiffness measurement predicts liver-related events in patients with chronic hepatitis C: A retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184404.	1.1	10
85	Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. <i>PLoS ONE</i> , 2016, 11, e0164455.	1.1	7
86	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 733.e1-733.e8.	2.8	34
87	Effectiveness and safety of an abacavir/lamivudine+rilpivirine regimen for the treatment of HIV-1 infection in naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3510-3514.	1.3	7
88	<i>Candida tropicalis</i> bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. <i>Journal of Infection</i> , 2015, 71, 385-394.	1.7	39
89	Dual treatment with lopinavir+ritonavir plus lamivudine versus triple treatment with lopinavir+ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 785-792.	4.6	131
90	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2015, 21, 491.e1-491.e10.	2.8	57

#	ARTICLE	IF	CITATIONS
91	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. <i>Clinical Microbiology and Infection</i> , 2015, 21, 684.e1-684.e9.	2.8	19
92	COPD patients with and without metabolic syndrome: clinical and functional differences. <i>Internal and Emergency Medicine</i> , 2014, 9, 419-425.	1.0	55
93	Epidemiology and predictive factors for early and late mortality in <i>Candida</i> bloodstream infections: a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2014, 20, O245-O254.	2.8	241
94	A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. <i>Eurosurveillance</i> , 2014, 19, .	3.9	12
95	Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2011, 18, 11-16.	1.0	67
96	Factors associated with mortality in patients with exacerbation of chronic obstructive pulmonary disease hospitalized in General Medicine departments. <i>Internal and Emergency Medicine</i> , 2011, 6, 47-54.	1.0	17
97	Plasma Interferon- γ -Inducible Protein-10 Can Predict Virologic Response to Hepatitis C Virus Therapy in HIV/HCV-Coinfected Patients With HCV Genotype 1. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 219-220.	0.9	5
98	Insulin Resistance Impairs Response to Interferon Plus Ribavirin in Patients Coinfected With HIV and Hepatitis C Virus. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 176-181.	0.9	15
99	Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. <i>Respiratory Medicine</i> , 2010, 104, 253-259.	1.3	98
100	Antagonistas de la aldosterona: ¿de la cirrosis a la insuficiencia cardiaca?. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 1001-1002.	0.6	0
101	Tenofovir y enfermedad β -sea en pacientes infectados por el VIH. <i>Revista EspaÃ±ola De Enfermedades MetabÃ³licas β-seas</i> , 2009, 18, 56-62.	0.0	1
102	Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59.	1.0	28
103	Insulin Resistance Is Associated With Advanced Liver Fibrosis and High Body Mass Index in HIV/HCV-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 109-110.	0.9	22
104	El Uso de la Eritropoyetina en el Manejo de la Insuficiencia CardÃaca. <i>MEDICRIT Revista De Medicina CrÃtica</i> , 2004, 1, .	0.1	1
105	CÃmo y dÃnde se encuentra la profesiÃn mÃdica: VisiÃn de un mÃdico especialista en formaciÃn. <i>Educacion Medica</i> , 0, 9, .	0.3	0
106	Bone mass in HIV male patients undergoing antiretroviral therapy. <i>Bone Abstracts</i> , 0, , .	0.0	0
107	Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14